HomeSwitzerlandBaseLaunch Announces Partnership with AbbVie

BaseLaunch Announces Partnership with AbbVie


BaseLaunch, a Basel, Switzerland-based biotech venture incubator, announced a partnership with and received an investment from AbbVie.

Through this investment, AbbVie gained access to life sciences deal flow in Central Europe.

BaseLaunch is an incubator and accelerator that helps scientists and entrepreneurs launch biotech companies. It serves as a growth platform for early-stage ventures developing therapeutics, helping them from inception through to Series A funding, providing financing and supporting the creation and growth.

Its partners now include AbbVie, Roche, Novo Nordisk, Johnson & Johnson, CSL, Pureos Bioventures, CMS and Bridge Biotherapeutics. Domain and regional partners include KPMG, Vossius & Partner, Alloy Therapeutics, Walder Wyss attorneys at law, WuXi AppTec, KPBMA, Lonza, Charles River Laboratories, Schrödinger, Wuxi Biologics, VISCHER as well as the Tech Park Basel, and the Switzerland Innovation Park Basel Area.

Since 2018, BaseLaunch has supported 24 early-stage biotech ventures, providing financing and assisting in all aspects of company creation and growth up to Series A financing. Of the 24 ventures, 10 have now collectively raised over US$ 600M in equity capital, and six have assets that have entered the clinic. Last year, T3 Pharma, a company initially supported by BaseLaunch, was acquired for US$ 500M.